Catherine J Wu

Catherine J Wu

UNVERIFIED PROFILE

Are you Catherine J Wu?   Register this Author

Register author
Catherine J Wu

Catherine J Wu

Publications by authors named "Catherine J Wu"

Are you Catherine J Wu?   Register this Author

99Publications

-Reads

Immunotherapy for glioblastoma: going viral.

Nat Med 2018 Aug;24(8):1094-1096

Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.

View Article
August 2018

DeTiN: overcoming tumor-in-normal contamination.

Nat Methods 2018 Jul 25;15(7):531-534. Epub 2018 Jun 25.

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

View Article
July 2018

Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Nat Rev Immunol 2018 Mar 11;18(3):168-182. Epub 2017 Dec 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article
March 2018

High-dimension single-cell analysis applied to cancer.

Mol Aspects Med 2018 Feb 30;59:70-84. Epub 2017 Aug 30.

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article
February 2018

SnapShot: Chronic Lymphocytic Leukemia.

Cancer Cell 2017 Nov;32(5):716-716.e1

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute, Cambridge, MA, USA.

View Article
November 2017

HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.

Cancer Cell 2017 07;32(1):1-3

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article
July 2017

Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

Cancer J 2017 Mar/Apr;23(2):115-124

From the *Department of Medical Oncology, Dana-Farber Cancer Institute; †Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; and ‡Massachusetts General Hospital Cancer Center, Boston; and §Broad Institute of MIT and Harvard, Cambridge, MA.

View Article
May 2017

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Cold Spring Harb Perspect Med 2017 Apr 3;7(4). Epub 2017 Apr 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215.

View Article
April 2017

Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.

J Clin Oncol 2017 Mar 13;35(9):984-993. Epub 2017 Feb 13.

All authors: Dana-Farber Cancer Institute; Romain Guièze and Catherine J. Wu, Harvard Medical School; Catherine J. Wu, Brigham and Women's Hospital, Boston; Romain Guièze and Catherine J. Wu, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Gregory Lazarian, U978 Institut National de la Santé et de la Recherche Médicale and Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny; and Romain Guièze, Centre Hospitalier Universitaire de Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.

View Article
March 2017

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.

Gynecol Oncol Rep 2017 Feb 29;19:42-45. Epub 2016 Dec 29.

Medical Gynecologic Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, USA.

View Article
February 2017

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Immunity 2017 02;46(2):197-204

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article
February 2017

Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction.

Immunity 2017 02;46(2):315-326

Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA; Harvard Medical School, Boston, MA, 02115, USA. Electronic address:

View Article
February 2017

Chronic lymphocytic leukaemia.

Nat Rev Dis Primers 2017 01 19;3:16096. Epub 2017 Jan 19.

CLL Research and Treatment Program, Feinstein Institute for Medical Research, Northwell Health, New Hyde Park, New York, USA.

View Article
January 2017

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.

Cancer Cell 2016 Nov 3;30(5):750-763. Epub 2016 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article
November 2016

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

N Engl J Med 2016 Jul;375(2):143-53

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.).

View Article
July 2016

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib.

Clin Cancer Res 2016 Apr 4;22(7):1547-9. Epub 2016 Feb 4.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article
April 2016

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.

Cell Rep 2016 Apr 14;15(4):857-865. Epub 2016 Apr 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article
April 2016

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Blood 2015 Jul 11;126(4):445-53. Epub 2015 Jun 11.

Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA; Cancer Program, Broad Institute, Cambridge, MA; and Division of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article
July 2015

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Nat Med 2015 Jun 25;21(6):572-80. Epub 2015 May 25.

1] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Pathology, Brigham &Women's Hospital, Boston, Massachusetts, USA.

View Article
June 2015

Haematological malignancies: at the forefront of immunotherapeutic innovation.

Nat Rev Cancer 2015 Apr 19;15(4):201-15. Epub 2015 Mar 19.

1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article
April 2015

Molecular and genetic properties of tumors associated with local immune cytolytic activity.

Cell 2015 Jan;160(1-2):48-61

The Broad Institute, Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Immunology and Inflammatory Diseases and Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129, USA. Electronic address:

View Article
January 2015

Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.

Cancer Cell 2014 Dec;26(6):813-825

Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology/Oncology, Children's Hospital, Boston, MA 02115, USA. Electronic address:

View Article
December 2014

Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition.

Authors:
Catherine J Wu

J Clin Invest 2014 Nov 20;124(11):4681-3. Epub 2014 Oct 20.

View Article
November 2014

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Blood 2014 Aug 28;124(7):1089-98. Epub 2014 Apr 28.

Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

View Article
August 2014

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

Blood 2014 Jul 2;124(3):453-62. Epub 2014 Jun 2.

Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

View Article
July 2014

Evolving understanding of the CLL genome.

Semin Hematol 2014 Jul 15;51(3):177-87. Epub 2014 May 15.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Broad Institute, Cambridge, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article
July 2014

Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics.

Genome Med 2013 29;5(5):47. Epub 2013 May 29.

Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA ; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

View Article
June 2014

Vaccines and melanoma.

Hematol Oncol Clin North Am 2014 Jun 3;28(3):559-69. Epub 2014 Apr 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA; Cancer Vaccine Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article
June 2014

HLA-binding properties of tumor neoepitopes in humans.

Cancer Immunol Res 2014 Jun 3;2(6):522-9. Epub 2014 Mar 3.

Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts

View Article
June 2014

Personal neoantigen cancer vaccines: The momentum builds.

Oncoimmunology 2014 25;3:e29311. Epub 2014 Jun 25.

Broad Institute of Harvard and MIT; Cambridge, MA USA ; Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.

View Article
June 2014

Understanding anti-leukemia responses to donor lymphocyte infusion.

Oncoimmunology 2014 17;3:e28187. Epub 2014 Mar 17.

Department of Medical Oncology; Dana-Farber Cancer Institute; Boston, MA USA ; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.

View Article
March 2014

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.

Biol Blood Marrow Transplant 2013 Nov 6;19(11):1537-45. Epub 2013 Sep 6.

Experimental Transplantation Immunology Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.

View Article
November 2013

Boosting leukemia-specific T cell responses in patients following stem cell transplantation.

Oncoimmunology 2013 Nov 10;2(11):e26587. Epub 2013 Oct 10.

Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.

View Article
November 2013

Getting personal with neoantigen-based therapeutic cancer vaccines.

Cancer Immunol Res 2013 Jul 7;1(1):11-5. Epub 2013 Apr 7.

Authors' Affiliations: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article
July 2013

SF3B1 mutations in chronic lymphocytic leukemia.

Blood 2013 Jun 8;121(23):4627-34. Epub 2013 Apr 8.

Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA

View Article
June 2013

CLL clonal heterogeneity: an ecology of competing subpopulations.

Authors:
Catherine J Wu

Blood 2012 Nov;120(20):4117-8

DANA-FARBER CANCER INSTITUTE.

View Article
November 2012

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.

Clin Cancer Res 2012 Oct 21;18(20):5761-72. Epub 2012 Aug 21.

Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts, USA.

View Article
October 2012

Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines.

Front Biosci (Landmark Ed) 2012 Jan 1;17:635-55. Epub 2012 Jan 1.

Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article
January 2012

Applications of next-generation sequencing to blood and marrow transplantation.

Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S151-60

Department of Haematology, Cambridge University, Cambridge, United Kinigdom.

View Article
January 2012

A coprecipitation-based validation methodology for interactions identified using protein microarrays.

Methods Mol Biol 2011 ;723:239-54

Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA.

View Article
June 2011

Data processing and analysis for protein microarrays.

Methods Mol Biol 2011 ;723:337-47

Cancer Vaccine Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article
June 2011

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.

Biol Blood Marrow Transplant 2011 Mar 24;17(3):421-8. Epub 2010 Sep 24.

Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article
March 2011

Components of the hematopoietic compartments in tumor stroma and tumor-bearing mice.

PLoS One 2011 Mar 25;6(3):e18054. Epub 2011 Mar 25.

Department of Physiology and Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.

View Article
March 2011

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.

Clin Cancer Res 2010 May 11;16(10):2729-39. Epub 2010 May 11.

Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Skin Disease Research Center, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article
May 2010

Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.

Clin Cancer Res 2010 Mar 16;16(5):1642-51. Epub 2010 Feb 16.

Division of Hematologic Malignancies, Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article
March 2010

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.

Cancer Res 2010 Feb 26;70(3):906-15. Epub 2010 Jan 26.

Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article
February 2010

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.

Cancer Res 2010 Feb 2;70(4):1344-55. Epub 2010 Feb 2.

Cancer Vaccine Center and Departments of Medical Oncology and Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article
February 2010

Revealing tumor immunity after hematopoietic stem cell transplantation.

Clin Cancer Res 2009 Jul 7;15(14):4515-7. Epub 2009 Jul 7.

Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article
July 2009

Induction of tumor immunity following allogeneic stem cell transplantation.

Adv Immunol 2006 ;90:133-73

Cancer Vaccine Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article
May 2009

Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.

Biol Blood Marrow Transplant 2008 Nov;14(11):1270-8

Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.

View Article
November 2008

A concentration-dependent analysis method for high density protein microarrays.

J Proteome Res 2008 May 5;7(5):2059-68. Epub 2008 Apr 5.

Cancer Vaccine Center and Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Institutes of Medicine, Boston, MA 02115, USA.

View Article
May 2008

Proteome informatics for cancer research: from molecules to clinic.

Proteomics 2007 Mar;7(6):976-91

Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article
March 2007

Evidence for ineffective erythropoiesis in severe sickle cell disease.

Blood 2005 Nov 9;106(10):3639-45. Epub 2005 Aug 9.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article
November 2005

Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.

Clin Cancer Res 2005 Jun;11(12):4504-11

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article
June 2005

Inflammatory myopathy associated with imatinib mesylate therapy.

J Clin Neuromuscul Dis 2004 Mar;5(3):119-21

From the Department of *Neurology, Lahey Clinic, Burlington, Massachusetts, and Tufts University School of Medicine, Boston, Massachusetts; the Department of daggerHematology/Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and the Department of double daggerNeurology, Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts.

View Article
March 2004